Evolus (EOLS) Cash from Investing Activities Growth (3y) (2021 - 2026)
Evolus (EOLS) Cash from Investing Activities Growth (3y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | -53.63% |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | -55.36% |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | 34.35% |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | 33.61% |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 15.92% |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | -2.45% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | -36.76% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Evolus | 550.51 Mn | 505.34 Mn | 57.18 Mn | -32.28% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -32.28% |
| Mar 31, 2026 | -49.02% |
| Dec 31, 2025 | -15.91% |
| Sep 30, 2025 | -33.89% |
| Jun 30, 2025 | -80.11% |
| Mar 31, 2025 | -92.47% |
| Dec 31, 2024 | -51.72% |
| Sep 30, 2024 | -310.44% |
| Jun 30, 2024 | -48.11% |
| Mar 31, 2024 | -29.40% |
| Dec 31, 2023 | -26.38% |
| Sep 30, 2023 | -26.38% |
| Jun 30, 2023 | -26.47% |
| Mar 31, 2023 | 77.72% |
| Dec 31, 2022 | -28.05% |
| Sep 30, 2022 | -26.54% |
| Jun 30, 2022 | -26.97% |
| Mar 31, 2022 | 85.17% |
| Jun 30, 2021 | -250.04% |